Journal of Pharmaceutical Sciences & Emerging Drugs

Short Communication A SCITECHNOL JOURNAL

Drug Activity in the Aging Population

Sareh Ali*

Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran

***Corresponding Author:** Sareh Ali, Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran; E mail: sareh@gmail.com

Received date: 22 May, 2024, Manuscript No. JPSED-24-148980;

Editor assigned date: 24 May, 2024, PreQC No. JPSED-24-148980 (PQ);

Reviewed date: 07 June, 2024, QC No. JPSED-24-148980;

Revised date: 14 June, 2024, Manuscript No. JPSED-24-148980 (R);

Published date: 21 June, 2024, DOI: 10.4172/2380-9477.1000193

Description

As the global population ages, understanding drug activity in older adults has become increasingly important for healthcare professionals [1]. Aging significantly affects pharmacokinetics and pharmacodynamics, which can lead to altered drug activity and increased risk of Adverse Drug Reactions (ADRs). The complexities of drug therapy in the aging population necessitate a comprehensive understanding of how physiological changes influence drug action, ensuring safe and effective treatment [2,3]. Aging is associated with numerous physiological changes that can impact drug activity. These changes include reduced renal and hepatic function, alterations in body composition and changes in receptor sensitivity. For instance, kidney function often declines with age, leading to decreased clearance of medications that are primarily eliminated through renal pathways [4]. This reduced clearance can result in drug accumulation and increased risk of toxicity. Similarly, liver function may decline, affecting the metabolism of drugs and altering their pharmacokinetic profiles [5].

Body composition changes also play a role in drug activity. Older adults typically experience increased body fat and decreased lean body mass and total body water. Lipophilic drugs, which are absorbed and stored in fatty tissues, may have prolonged half-lives in older adults, leading to prolonged drug effects. Conversely, hydrophilic drugs may require dose adjustments due to decreased total body water [6]. These changes necessitate careful consideration of dosing regimens to avoid adverse effects and ensure therapeutic efficacy. In addition to pharmacokinetic changes, older adults may exhibit altered pharmacodynamics, meaning the way drugs exert their effects can change with age [7]. Older individuals may have increased sensitivity to certain medications, such as sedatives, antipsychotics and anticoagulants. This heightened sensitivity can result in exaggerated drug effects, necessitating lower doses to achieve the desired therapeutic outcome [8,9]. Furthermore, polypharmacy defined as the concurrent use of multiple medications is prevalent among older adults due to the higher prevalence of chronic conditions. This practice increases the risk of drug-drug interactions, which can further complicate drug activity and amplify the risk of ADRs. Therefore, healthcare providers must conduct thorough medication reviews and consider the overall medication regimen to minimize potential interactions and adverse effects [10]. To optimize drug activity in the aging population, individualized care is paramount. Healthcare providers should assess each patient's unique health status, including renal and liver function, comorbidities and potential for polypharmacy.

Conclusion

Regular monitoring is also essential in managing drug therapy for older adults. Routine assessments of drug efficacy and safety can help identify potential issues early, allowing for timely adjustments to the treatment plan. In particular, monitoring renal and liver function can provide valuable information for dose adjustments and prevent drug accumulation. Drug activity in the aging population is influenced by a myriad of factors, including physiological changes, altered pharmacodynamics and the prevalence of polypharmacy. To ensure safe and effective medication management, healthcare providers must adopt a patient centered approach that emphasizes individualized care, careful monitoring and consideration of the unique challenges faced by older adults. By doing so, healthcare professionals can improve treatment outcomes and enhance the quality of life for this vulnerable population, ensuring that aging does not compromise access to effective pharmacotherapy.

References

1. Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, et al. (2013) Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: A population-based study. Drugs Aging 30:321-330.
2. Mann Jr DE (1965) Biological aging and its modification of drug activity. J Pharm Sci 54(4):499-510.
3. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56(2):163-184.
4. Le Couteur DG, McLachlan AJ, de Cabo R (2012) Aging, drugs, and drug metabolism. J Gerontol A Biol Sci Med Sci 67(2): 137-139.
5. Siegel EB (1982) Drugs and the aging. Regul Toxicol Pharmacol 2(4):287-295.
6. Hunt NJ, McCourt PA, Kuncic Z, Le Couteur DG, Cogger VC (2022) Opportunities and challenges for nanotherapeutics for the aging population. Frontiers in Nanotechnology 4:832524.
7. Wynne H (2005) Drug metabolism and ageing. J Br Menopause Soc 11(2):51-56.
8. Vuyk J (2003) Pharmacodynamics in the elderly. Best Practice Research Clinical Anaesthesiology 17(2):207-218.
9. Ginsberg G, Hattis D, Russ A, Sonawane B (2005) Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 113(9):1243-1249.
10. Hutchison LC, O'Brien CE (2007) Changes in pharmacokinetics and pharmacodynamics in the elderly patient. Journal of Pharmacy Practice 20(1):4-12.

Citation: *Ali S (2024) Drug Activity in the Aging Population. J Pharm Sci Emerg Drugs 12:3.*